Vivos Therapeutics, Inc. (VVOS)
NASDAQ: VVOS · Real-Time Price · USD
0.5720
-0.0417 (-6.79%)
Jun 12, 2026, 4:00 PM EDT - Market closed

Vivos Therapeutics Stock Forecast

Stock Price Forecast

According to 3 analysts polled by S&P Global, Vivos Therapeutics stock has a consensus rating of "Buy" and an average price target of $2.45. The average 1-year stock price forecast is 328.32% higher than the current stock price, while the lowest is $1.75 (+205.94%) and the highest is $3.10 (+441.96%).

Price Target: $2.45 (+328.32%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$1.75$2.45$2.50$3.10
Change+205.94%+328.32%+337.06%+441.96%
* Price targets were last updated on Apr 22, 2026.

Analyst Ratings

The average analyst rating for Vivos Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy222222
Buy000000
Hold111111
Sell000000
Strong Sell000000
Total333333

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Ascendiant
Ascendiant
Buy
Reiterates
$5.5$3
BuyReiterates$5.5$3+424.48%Apr 22, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$2.5
BuyReiterates$2.5+337.06%Apr 17, 2026
Alliance Global Partners
Alliance Global Partners
Hold
Maintains
$2.5$1.75
HoldMaintains$2.5$1.75+205.94%Apr 17, 2026

Financial Forecast

Revenue This Year
23.12M
from 17.44M
Increased by 32.55%
Revenue Next Year
34.51M
from 23.12M
Increased by 49.26%
EPS This Year
-1.82
from -2.07
EPS Next Year
-0.84
from -1.82
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
16.89M16.02M13.80M15.03M17.44M23.12M
Revenue Growth
29.23%-5.10%-13.87%8.91%16.05%32.55%
Gross Profit
12.60M10.02M8.27M9.02M10.54M14.03M
Gross Margin
74.65%62.52%59.93%60.00%60.44%60.67%
Operating Income
-19.47M-25.03M-17.30M-11.17M-19.89M-23.82M
Net Income
-20.29M-23.85M-13.58M-11.14M-21.17M-27.35M
EPS
-----2.07-1.82
No. Analysts
-----2
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue20262027
High24.1M
Avg23.1M
Low22.1M

Revenue Growth

Revenue Growth20262027
High
38.4%
Avg
32.5%
Low
26.7%

EPS Forecast

EPS20262027
High-1.50
Avg-1.82
Low-2.14

EPS Growth

EPS Growth20262027
High-
Avg-
Low-